Blood Biomarkers in Parkinson's Disease: Current Research and Diagnostic Reality

No blood test currently diagnoses Parkinson's disease (PD). Diagnosis remains clinical, based on motor features (bradykinesia plus rigidity or tremor), response to dopaminergic therapy, and exclusion of mimics. However, research into blood-based biomarkers is active and promising.

Promising Biomarkers Under Investigation

• α-Synuclein (α-Syn): Misfolded α-syn aggregates form Lewy bodies. Peripheral α-syn species (total, oligomeric, phosphorylated) in plasma/serum/exosomes correlate with PD, but overlap with controls limits diagnostic specificity.
• Neurofilament Light Chain (NfL): Marker of axonal injury. Elevated in PD vs. controls; correlates with disease severity and progression. Also elevated in ALS, MS, FTD—limited disease specificity.
• Tau & Phospho-Tau: Alzheimer's co-pathology common in PD; plasma p-tau181/217 may help distinguish PD from PD-dementia or AD.
• Inflammatory Markers: CRP, IL-6, TNF-α, IFN-γ—often elevated in PD, reflecting neuroinflammation. Non-specific.
• Metabolomic/Lipidomic Profiles: Panels of small molecules (e.g., urate, sphingolipids) show classification potential in discovery cohorts.
• Genetic Markers: GBA, LRRK2, SNCA variants increase risk; not diagnostic alone but enrich pre-test probability.
• Exosomal Neuronal Markers: Neuron-derived exosomes (L1CAM+) carrying α-syn, NfL, DJ-1—enhance CNS specificity.

Current Clinical Utility

• Research Use Only: No validated, FDA-cleared blood test for PD diagnosis or prognosis.
• Supportive Role: Biomarkers may eventually aid prodromal detection (e.g., RBD cohorts), subtyping, or monitoring therapeutic target engagement in trials.
• Standard Diagnosis: Clinical criteria (MDS), DaTscan (dopamine transporter SPECT) for uncertain cases.

Large longitudinal cohorts (PPMI, BioFIND, PDBP) are validating biomarker trajectories. Until then, blood testing in PD serves to exclude mimics (thyroid, B12, copper, Wilson's, infectious/autoimmune panels).